AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?

Breast Cancer Research

Volumn 15, Issue 5, 2013, Pages

  Heideman, Marinus R ^a   Hynes, Nancy E ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER PROGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; TRANSACTIVATION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; FEMALE; METABOLISM; NOTE; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84887566161     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3564     Document Type: Article

References (15)

1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134. 10.1016/j.cell.2010.06.011, 2914105, 20602996.
2. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012, 12:553-563.
3. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010, 7:683-692. 10.1038/nrclinonc.2010.154, 20877296.
4. Crown J, O'Shaughnessy J, Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 2012, 23(Suppl 6):vi56-vi65. 10.1093/annonc/mds196, 23012305.
5. Meyer AS, Miller MA, Gertler FB, Lauffenburger DA. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal 2013, 6:ra66. 10.1126/scisignal.2004155, 23921085.
6. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011, 30:1436-1448. 10.1038/onc.2010.509, 21057535.
7. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012, 44:852-860. 10.1038/ng.2330, 3408577, 22751098.
8. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013, 19:279-290. 10.1158/1078-0432.CCR-12-1558, 23091115.
9. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
10. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26. 10.1126/scitranslmed.3002003, 3132801, 21430269.
11. Hynes NE, Ingham PW, Lim WA, Marshall CJ, Massague J, Pawson T. Signalling change: signal transduction through the decades. Nat Rev Mol Cell Biol 2013, 14:393-398. 10.1038/nrm3581, 23636498.
12. Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, Yip GW, Bay BH, Tan PH. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011, 13:R35. 10.1186/bcr2857, 3219198, 21457545.
13. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S, Mackay A, Reis RM, Hornick JL, Pereira EM, Baltazar F, Fletcher CD, Ashworth A, Lakhani SR, Schmitt FC. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006, 209:445-453. 10.1002/path.2004, 16739104.
14. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005, 65:5996-6000. discussion 6000-6001, 10.1158/0008-5472.CAN-05-0699, 16024596.
15. Gunasinghe NP, Wells A, Thompson EW, Hugo HJ. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 2012, 31:469-478. 10.1007/s10555-012-9377-5, 22729277.